Spect

Value-based retinal screening in primary care to prevent blindness.

Spect is active in the healthcare space based in Palo Alto, CA, USA; Remote, founded in 2022.

Profile

Vision Disease cause innumerable cases of preventable blindness globally - 415 million diabetic patients worldwide are susceptible to Diabetic Retinopathy (DR), Glaucoma, and more. Current screening protocols for vision disease require ophthalmologists to manually diagnose patients through visual assessment of the fundus. Given the large number of diabetes patients in various communities, this process is expensive, inefficient, and an undue burden on eye clinics.

Spect is positioned in healthcare, a segment that rewards a clear, focused offering.

Its base of operations is Palo Alto, CA, USA; Remote.

It is recorded at the Summer 2017 stage.

The company reports a headcount in the 7 range.

Website: www.getspect.com